AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

843.542

-12.845-1.50%

Number of Gainers:12

Number of Losers:17

Number of Flat:17

PE:- -

High:856.440

Open:856.387

Low:842.294

Close:856.387

Loading ...

Looking for last-minute dividends? 25 ASX shares going ex-dividend next week

Polynovo CEO Swami Raote hands in his notice amid rumblings of board discontent

Business News Australia

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index

BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial

BRIEF-Mesoblast Added To S&P Asx200 Index

Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today

Banks, energy stocks pull down Australian shares; investors assess China stimulus

Mesoblast Joins S&P/ASX 200; Shares Down 4%

MT Newswires Live

Mesoblast Added to S&P ASX200 Index-Msb.ax

THOMSON REUTERS

Anatara Lifesciences Ltd - Seeks Trading Halt Pending Announcement Regarding Update on Phase Ii Garp-Ibs Trial

THOMSON REUTERS

Why Mesoblast shares could still be dirt cheap even after 700% gain

Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development

MT Newswires Live

Invion Terminates Share Purchase Agreement with Lind

MT Newswires Live

The 'crucial' growth metric that makes CSL shares a buy today

Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":843.54193,"timestamp":1741582799994,"preClose":856.387,"halted":0,"volume":81305322,"delay":0,"changeRate":-0.014999,"change":-12.845093,"amount":116338255,"amplitude":0.016518,"prevYearClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":856.43976,"amplitude":0.016518,"preClose":856.387,"low":842.2942,"latestPrice":843.54193,"volume":81305322,"delay":0,"open":856.387,"prevYearClose":936.801,"prevWeekClose":856.387,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"sixtyDayClose":933.014,"secType":"PLATE","market":"AU","turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75,"timestamp":1741582799994,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":17,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517941641","title":"Looking for last-minute dividends? 25 ASX shares going ex-dividend next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2517941641","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517941641?lang=en_us&edition=fundamental","pubTime":"2025-03-07 02:30","pubTimestamp":1741285800,"startTime":"0","endTime":"0","summary":"Stacks of ASX shares will begin trading ex-dividend next week.  It's handy to know when the ASX shares you already own are due to go ex-dividend.  If you feel like increasing your holdings, you may wa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/07/looking-for-last-minute-dividends-25-asx-shares-going-ex-dividend-next-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7506","PWH.AU","BK7128","BK7141","BK7062","BK7104","PPT.AU","ADH.AU","BK7002","BK7016","BK7051","BK7501","NEC.AU","CSL.AU","BK7511","PRU.AU","BK7049","MMS.AU","BK7052","BK7057","BK7113","BK7030","SGH.AU","BXB.AU","BK7508","BK7083","KGN.AU","BAP.AU","CAR.AU","BK7505","IRE.AU","NWS.AU","QAN.AU","SUL.AU","BK7153","DSK.AU","BRG.AU","WTC.AU","BK7061","BK7107","BK7504","HLO.AU","ING.AU","REG.AU","VUL.AU","BK7070","YAL.AU","DTL.AU","BK7031","BK7038"],"gpt_icon":0},{"id":"2517274801","title":"Polynovo CEO Swami Raote hands in his notice amid rumblings of board discontent","url":"https://stock-news.laohu8.com/highlight/detail?id=2517274801","media":"Business News Australia","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517274801?lang=en_us&edition=fundamental","pubTime":"2025-03-07 00:00","pubTimestamp":1741276800,"startTime":"0","endTime":"0","summary":"Rumblings of discontent within the board of Melbourne-based biotech...","market":"nz","thumbnail":"https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67ca567a2326d.jpg?v=2&m=99e68f2e18115f1fd062f65cea94ea33&lqip(10)","type":0,"news_type":0,"thumbnails":["https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67ca567a2326d.jpg?v=2&m=99e68f2e18115f1fd062f65cea94ea33&lqip(10)"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessnewsaustralia.com/articles/polynovo-ceo-swami-raote-hands-in-his-notice-amid-rumblings-of-board-discontent.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"businessau_stock","symbols":["BK7508","XJO.AU","XAO.AU","PNV.AU","XKO.AU","BK7126"],"gpt_icon":0},{"id":"2517337907","title":"Hoping to bag the boosted dividend from CSL shares? Here's your deadline…","url":"https://stock-news.laohu8.com/highlight/detail?id=2517337907","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517337907?lang=en_us&edition=fundamental","pubTime":"2025-03-06 11:03","pubTimestamp":1741230187,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares are down 1.08% to $261.40 per share on Thursday. It's a red day for the broader market, too, with the S&P/ASX 200 Index  down 0.6%.  Next Monday, CSL shares will begin trading ex-dividend.  That means investors have only today and tomorrow to scoop up some CSL shares to qualify for the next dividend payment. CSL shares will pay a 9% higher interim dividend of US$1.30 per share unfranked on 9 April.  Australian investors will receive their CSL dividend in AU dollars.  Based on the exchange rate at the time, CSL will confirm the interim dividend amount in AU terms next Thursday.  How did CSL's 1H FY25 results look?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/06/hoping-to-bag-the-boosted-dividend-from-csl-shares-heres-your-deadline/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7511","LU0728928796.USD","BK7508","LU1169589451.USD","CSL","BK7501","CSL.AU","LU1169590202.USD","SGXZ23171101.USD","SG9999004303.SGD","XJO.AU","BK4086"],"gpt_icon":0},{"id":"2517740903","title":"BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index","url":"https://stock-news.laohu8.com/highlight/detail?id=2517740903","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517740903?lang=en_us&edition=fundamental","pubTime":"2025-03-06 10:53","pubTimestamp":1741229639,"startTime":"0","endTime":"0","summary":"BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index** Shares of biotech firm Mesoblast MSB.AX down 6.5% at A$2.245** MSB falls as much as 7.1% earlier in the day, hitting its lowest since December 18, 2024** First day of trading as a constituent of the S&P/ASX 200 benchmark index .AXJO, which is trading 0.7% lower as of 0223 GMT** Arcadium Lithium ALTM.N, which is being acquired by Rio Tinto RIO.L, RIO.AX, removed from index at start of trading on March 6 ** Melbourne-based MSB, which is developing medicines to treat life-threatening inflammatory conditions, top loser in the benchmark index** MSB's Nasdaq-listed shares MESO.O closed 0.8% higher overnight after a cumulative 14.2% drop in the previous two sessions** MSB reported HY loss of $47.9 million last week, compared with a $32.5 million loss a year earlier** MSB shares down 28% this year, following a 10-fold surge last year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL6N3PP06E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0630314457.HKD","LU0171293334.USD","LU0788109121.HKD","LU1430597077.USD","LU0345777147.USD","LU0612318385.USD","LU1064927863.SGD","BK4139","LU0831103253.SGD","LU0612318971.USD","IE00BQJZX424.USD","BK4109","BK7067","BK7508","LU1130305938.SGD","LU0266512127.USD","LU0456854461.SGD","LU0330918003.SGD","IE00B3M56506.USD","RIO.UK","MESO","LU0345781412.USD","LU0345777659.USD","LU0654597011.USD","MSB.AU","LU1023059493.AUD","LU0955669360.SGD","LU0505663152.USD","LU1078025761.USD","BK5111","SG9999001143.SGD","LU0011963245.USD","LU0345780950.USD","SG9999002521.SGD","ALTM","LU0898667661.SGD","BK4144","LU0075056555.USD","IE00BWDBJ516.SGD","IE0034235071.USD","BK7501"],"gpt_icon":0},{"id":"2517972605","title":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972605?lang=en_us&edition=fundamental","pubTime":"2025-03-06 09:37","pubTimestamp":1741225061,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs TrialMarch 6  - Anatara Lifesciences Ltd ANR.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT REGARDING  UPDATE ON PHASE II GARP-IBS TRIALFurther company coverage: ANR.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2517697113","title":"BRIEF-Mesoblast Added To S&P Asx200 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697113?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:55","pubTimestamp":1741222527,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Added To S&P Asx200 IndexMarch 6 (Reuters) - Mesoblast MSB.AX:ADDED TO S&P ASX200 INDEX-MSB.AXFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK4139","BK7508","BK7501","MESO","MSB.AU"],"gpt_icon":0},{"id":"2517423971","title":"Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517423971","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517423971?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:54","pubTimestamp":1741222475,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is out of form again on Thursday and sliding into the red. At the time of writing, the benchmark index is down 0.45% to 8,105.4 points. Four ASX shares that are falling","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/06/why-appen-mesoblast-rio-tinto-and-woodside-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MESO","BK7507","RIO.AU","APX.AU","BK4139","XJO.AU","BK7095","BK7067","BK7142","BK7501","BK7508","BK7511","MSB.AU","WDS.AU","BK7061","BK7503"],"gpt_icon":0},{"id":"2517787976","title":"Banks, energy stocks pull down Australian shares; investors assess China stimulus","url":"https://stock-news.laohu8.com/highlight/detail?id=2517787976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517787976?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:24","pubTimestamp":1741220697,"startTime":"0","endTime":"0","summary":"Banks, energy stocks pull down Australian shares; investors assess China stimulus March 6 (Reuters) - Australian shares fell on Thursday, dragged down by energy and bank stocks, while investors assess","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL3N3PP00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1130305938.SGD","BK7078","BK7501","BK5111","BK7508","LU0266512127.USD","LU0831103253.SGD","STO.AU","IE0034235071.USD","LU0011963245.USD","BK7511","LU1430597077.USD","BK7067","IE00B3M56506.USD","ALL.AU","SG9999002521.SGD","LU0075056555.USD","BK7142","FMG.AU","RIO.UK","LU0898667661.SGD","LU0612318385.USD","LU0345777147.USD","BK7507","LU0456854461.SGD","IE00BWDBJ516.SGD","LU0171293334.USD","LU0330918003.SGD","LU0612318971.USD","CBA.AU","LU0345780950.USD","LU0788109121.HKD","LU1078025761.USD","SG9999001143.SGD","WBC.AU","WDS.AU","IE00BQJZX424.USD","CSL.AU","LU0955669360.SGD","BK7129","LU0505663152.USD","LU0654597011.USD","LU1064927863.SGD","LU0345781412.USD","LU0345777659.USD","LU1023059493.AUD","BK7135","LU0630314457.HKD"],"gpt_icon":0},{"id":"2517975351","title":"Mesoblast Joins S&P/ASX 200; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975351?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:45","pubTimestamp":1741218340,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) joined the S&P/ASX 200 Index before market open on Thursday, according to a same-day filing with the Australian bourse.The company, which develops treatment for life-threatening inflammatory conditions, saw shares down almost 4% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","MESO","BK7508","BK7067","MSB.AU","BK4139","XAO.AU","XJO.AU","BK7501"],"gpt_icon":0},{"id":"2517365927","title":"Mesoblast Added to S&P ASX200 Index-Msb.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2517365927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517365927?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:09","pubTimestamp":1741212594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK4139","MSB.AU","MESO","BK7508","BK7067"],"gpt_icon":0},{"id":"2517227539","title":"Anatara Lifesciences Ltd -  Seeks Trading Halt Pending Announcement Regarding  Update on Phase Ii Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517227539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517227539?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:03","pubTimestamp":1741212213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2517929424","title":"Why Mesoblast shares could still be dirt cheap even after 700% gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929424","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517929424?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:58","pubTimestamp":1741208280,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  shares have been on fire over the past 12 months. During this time, the biotechnology company's shares have rallied around 700%. To put that into context, a $5,000 investment in its shares a year ago would now be worth approximately $40,000. But if you thought those gains were over, think again!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/06/why-mesoblast-shares-could-still-be-dirt-cheap-even-after-700-gain/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK7067","MESO","BK7508","MSB.AU","BK4139"],"gpt_icon":0},{"id":"2517578469","title":"Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2517578469","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517578469?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:35","pubTimestamp":1741152914,"startTime":"0","endTime":"0","summary":"Race Oncology  signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.Its shares rose 3% on market close on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7067","BK7508","XJO.AU","XAO.AU","RAC.AU"],"gpt_icon":0},{"id":"2517542499","title":"Invion Terminates Share Purchase Agreement with Lind","url":"https://stock-news.laohu8.com/highlight/detail?id=2517542499","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517542499?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:00","pubTimestamp":1741150845,"startTime":"0","endTime":"0","summary":"Invion  issued a termination notice for the share purchase agreement with Lind Global Fund II dated June 27, 2024, and will be repaying the latest tranche installment to Lind, according to a Wednesday Australian bourse filing.The Agreement is a staged private placement in monthly installments of AU$100,000 per month, which may be raised up to AU$500,000 per month, over a 12-month period from June 2024, the filing added.The company said it will also repay the latest installment of AU$250,000 provided by Lind at a 5% premium.The deal termination carries no cost for the life-science firm, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7509","IVX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2517957187","title":"The 'crucial' growth metric that makes CSL shares a buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517957187","media":"MotleyFool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517957187?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:22","pubTimestamp":1741148553,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares can't escape the wider market sell-down today. Shares in the S&P/ASX 200 Index biotech stock are down 0.22% in afternoon trade on Wednesday, changing hands for $264.12 apiece. For some context, the ASX 200 is down 0.84% at this same time. But looking to the year ahead, Ord Minnett's Tony Paterno has an optimistic outlook on CSL stock . Time to buy CSL shares?For the full year FY 2025, management is forecasting year on year revenue growth of 5% to 7% on a constant currency basis. CSL expects fiscal year 2025 net profit after tax and amortisation  to be in the range of US$3.2 billion to US$3.3 billion on a constant currency basis. That equates to profit growth of approximately 10% to 13%. CSL shares are down 7% over the past year, not including dividends.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/the-crucial-growth-metric-that-makes-csl-shares-a-buy-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0728928796.USD","LU1169589451.USD","BK7508","XJO.AU","BK7067","BK7511","LU1169590202.USD","CSL","BK7501","SG9999004303.SGD","BK4086","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2517953396","title":"Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517953396","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517953396?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:58","pubTimestamp":1741143496,"startTime":"0","endTime":"0","summary":"Immuron  entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.Company shares were down nearly 3% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","BK7067","XAO.AU","XJO.AU","IMC.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":11,"pageCount":3,"totalSize":172}]}}